BioCentury
ARTICLE | Clinical News

Vonapanitase: Ph I started

November 11, 2016 8:29 PM UTC

Proteon began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial to evaluate a single perivascular injection of vonapanitase delivered via micro-infusion catheter in up to 40 pati...

BCIQ Company Profiles

Proteon Therapeutics Inc.